![Quiver Logo](/static/img/logo-icon.png)
![BIAF logo](https://quiver-logos.s3.us-east-2.amazonaws.com/biaf.png)
bioAffinity Technologies, Inc. Common Stock
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BIAF Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of BIAF by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BIAF's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to BIAF
Recent picks made for BIAF stock on CNBC
ETFs with the largest estimated holdings in BIAF
Flights by private jets registered to BIAF
![Quiver Logo](/static/img/logo-icon.png)